TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03467295

Intervention type: PROCEDURE
Intervention: Surgery
Description: For patient in surgically treated group, surgical removal of intracerebral CMs by craniotomy is performed according to the principles as follows: less transgression of normal brain tissue; identification and protection of eloquent brain tissue; sparing associated developmental venous anomaly; hemosiderin rim resection for non-eloquent and superficial CMs and sparing yellowish tissue for eloquent and deep ones; Extended resections (mesial resection, standard temporal lobe resection) are recommend for epileptogenic CMs based on intra-operative EEG.

Intervention type: PROCEDURE
Intervention: Observation
Description: Observation is performed in conservatively treated patients with best medicine and supportive treatment, such as antiepileptic drugs, analgesic drugs and neurotrophic drugs. For patients with underlying diseases such as hypertension, hyperlipidemia or diabetes mellitus, after consulting with the relevant experts, the patients can be treated accordingly.
Study: NCT01419015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN XT NovaFlex delivery system
Description: Transcatheter aortic valve implantation via transfemoral approach.
Study: NCT03289741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Patients will receive three monthly injections every 28 (+/- 3) days. Octreotide LAR for 3 injections followed by lanreotide for 3 injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Patients will receive three monthly injections every 28 (+/- 3) days. Octreotide LAR for 3 injections followed by lanreotide for 3 injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAR Lanreotide
Description: Patients will receive three monthly injections every 28 (+/- 3) days. Lanreotide for 3 injections followed by octreotide LAR for 3 injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAR Lanreotide
Description: Patients will receive three monthly injections every 28 (+/- 3) days. Lanreotide for 3 injections followed by octreotide LAR for 3 injections

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Baseline questionnaire, Post-treatment questionnaire (after the first 3 injections), Preference questionnaire and Pain Score Diary.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Baseline questionnaire, Post-treatment questionnaire (after the first 3 injections), Preference questionnaire and Pain Score Diary.
Study: NCT00180271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillation
Description: Boston Scientific Corporation Market Released Cardiac Resynchronization therapy with defibrillation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Cardioverter Defibrillator (ICD)
Description: Boston Scientific Corporation Market Released Implantable Cardioverter Defibrillator
Study: NCT02990455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced nicotine cigarettes
Description: Participants will be assigned to undergo two experimental conditions (i.e., exclusive smoking of RNC Low or Moderate in their home environment for 7 days) in a double-blind, randomized, crossover design. The two experimental conditions will be separated by a 7-day period of return to smoking of participants' own brand of cigarette.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced nicotine cigarettes
Description: Participants will be assigned to undergo two experimental conditions (i.e., exclusive smoking of RNC Low or Moderate in their home environment for 7 days) in a double-blind, randomized, crossover design. The two experimental conditions will be separated by a 7-day period of return to smoking of participants' own brand of cigarette.
Study: NCT03467256

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Description: anti-CD19 chimeric antigen receptor - transduced T-cell given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: given IV
Study: NCT01887106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1205 single ascending doses, oral suspension
Description: Single dose, oral suspension at 10 mg/mL or 50 mg/mL, starting dose of 10mg escalating up to 800mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single ascending doses, oral suspension
Description: Single dose, oral suspension matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1205, multiple ascending doses, oral suspension
Description: Multiple doses, daily for 14 days, oral suspension at 10 mg/mL or 50 mg/mL, anticipated doses: 100mg to 400mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, multiple ascending doses, oral suspension
Description: Multiple doses, daily for 14 days, oral suspension matching placebo
Study: NCT00538746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIPAP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSV
Study: NCT03467256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: given IV
Study: NCT03821883

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo qd
Study: NCT00454883

Intervention type: DRUG
Intervention: ziprasidone
Description: Ziprasidone 40 mg twice daily taken with food. Daily dosage may subsequently be adjusted on the basis of individual clinical status up to a maximum of 80 mg twice daily. If indicated, the maximum recommended dose may be reached as early as day 3 of treatment.
Study: NCT03467256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: given IV
Study: NCT00921726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: Continuous (800 mg in Regimen A, 3600 mg in Regimen C) and intermittent (3600 mg in Regimen D) infusion
Study: NCT01061177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib was supplied by Novartis as 150 mg hard gelatin capsules in bottles. Nilotinib was dosed on a flat scale and not dosed by body weight. This form of supply was continued for all participants entered into the core study.
Study: NCT01180985

Intervention type: DEVICE
Group type: OTHER
Intervention: galyfilcon A prototype lens
Description: silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: galyfilcon A prototype lens
Description: silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: comfilcon A
Description: silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: comfilcon A
Description: silicone hydrogel contact lens
Study: NCT01796067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational and Family Weight Loss
Description: This group will receive the comprehensive motivational and family weight loss intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational and Family Weight Loss
Description: This group will receive the comprehensive motivational and family weight loss intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Health Education
Description: This group will receive the comprehensive basic health education intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Health Education
Description: This group will receive the comprehensive basic health education intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Intervention
Description: Participants will receive the online tailored weight loss intervention program after they have either received the motivational plus family weight loss program or basic health face-to-face program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Intervention
Description: Participants will receive the online tailored weight loss intervention program after they have either received the motivational plus family weight loss program or basic health face-to-face program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Control
Description: Participants will receive the online control program after they have either received the motivational plus family weight loss program or the basic health education program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Control
Description: Participants will receive the online control program after they have either received the motivational plus family weight loss program or the basic health education program.
Study: NCT04565119

Intervention type: OTHER
Intervention: No intervention. This is an observational study.
Description: There are no interventions being tested in the Bio-BOOST study.
Study: NCT04593056

Intervention type: DRUG
Intervention: Warfarin
Description: Warfarin dispensing claim is used as the reference

Intervention type: DRUG
Intervention: Rivaroxaban
Description: Rivaroxaban dispensing claim is used as the exposure
Study: NCT04065958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga-mindfulness
Description: Body-mind therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education and physiotherapy
Description: Lectures and physiotherapy
Study: NCT00538746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSV + CPAP
Study: NCT02663479

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cardiopressin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02394795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Study: NCT02581618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning
Description: Blood pressure cuff inflation up to 200mmHg in the non-dominant arm before guiding catheter engagement
Study: NCT02307656

Intervention type: DRUG
Group type: OTHER
Intervention: Atazanavir
Study: NCT02307656

Intervention type: DRUG
Group type: OTHER
Intervention: Cobicistat

Intervention type: DRUG
Group type: OTHER
Intervention: Active Pharmaceutical Ingredient
Study: NCT02168296

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based ingredient added to starchy meal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based ingredient added to starchy meal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based ingredient added to liquid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based ingredient added to liquid

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No Plant-based ingredient
Study: NCT01492296

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopy after short fasting
Description: patients were evaluated with endoscopy after fasting for two hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional fasting
Description: patients were evaluated after fasting for 8 hours
Study: NCT01572818

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phlebotomy
Description: 7 ml/kg without exceeding 500 mL

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary and lifestyle counseling
Description: dietary and lifestyle counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary and lifestyle counseling
Description: dietary and lifestyle counseling
Study: NCT02203669

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home therapy
Description: Study subjects complete home therapy independently for four (4) weeks based on handouts of exercises adapted for post-operative breast reconstruction patients along with an instructional handout for stretching complied by a certified occupational therapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured In-Office Therapy
Description: Study subjects will participate in Structured In-Office Therapy twice a week for four (4) weeks. Each visit will last approximately sixty (60) minutes. Subjects will receive therapy instruction by a certified occupational therapist on upper extremity stretching, relaxation, cardio rehabilitation, and strength training. These subjects will also receive exercise and stretching handouts to use at home between therapy visits.
Study: NCT04209205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 3 mg/kg
Description: AIN457 3 mg/kg delivered by i.v. infusion
Study: NCT03865459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video group
Description: Patients in the video group started to watch the relaxing video about 5-10 minutes before cystoscopy, and continued to watch video during the whole procedure.
Study: NCT02267226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octafibrin
Study: NCT03441347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific rehabilitation program
Description: 17-week specific and personalised rehabilitation program. The program starts with a visit to the Plexus out patient clinic in week 1. During this visit, the patient will be examined by a multidisciplinary team, consisting of a rehabilitation physician, neurologist, physical therapist and occupational therapist, which will form a rehabilitation treatment plan. This treatment plan is implemented through 4 weekly sessions in week 2-5, 2 biweekly sessions in week 6-9 and 2 monthly sessions in week 10-17 . Each treatment session involves one hour of physical- and one hour of occupational therapy.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Specific rehabilitation program
Description: 17-week specific and personalised rehabilitation program. The program starts with a visit to the Plexus out patient clinic in week 1. During this visit, the patient will be examined by a multidisciplinary team, consisting of a rehabilitation physician, neurologist, physical therapist and occupational therapist, which will form a rehabilitation treatment plan. This treatment plan is implemented through 4 weekly sessions in week 2-5, 2 biweekly sessions in week 6-9 and 2 monthly sessions in week 10-17 . Each treatment session involves one hour of physical- and one hour of occupational therapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Participants will receive their usual care for 17 weeks, which may vary for each individual
Study: NCT03742115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2 twice weekly for 2 weeks and then weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2 weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: 0.5 g/kg, once every 4 weeks
Study: NCT03250156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBAT with proctored practice
Description: The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion. Participants will have proctored practice and complete the assigned, out-of-class mindfulness exercises during the duty day as party of their physical training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MBAT with non-proctored practice
Description: The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion.Participants will not have proctored practice and will complete the assigned, out-of-class mindfulness exercises on their own.
Study: NCT01300364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reboxetine
Description: 8mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Reboxetine
Description: 8mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram (SSRI)
Description: 30mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: citalopram (SSRI)
Description: 30mg/day
Study: NCT01932658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
Study: NCT00045487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-774
Description: OSI-774 is an orally active, potent, selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase.
Study: NCT03858608

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Counterweight Plus
Description: Total diet replacement followed by food reintroduction and weight maintenance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual asthma care
Description: Usual asthma management
Study: NCT04248062

Intervention type: OTHER
Intervention: Survey
Description: Survey: 38 preselected patient and parent reported outcomes; rating scale: 9 point likert scale (1=not at all important - 9=very important)

Intervention type: OTHER
Intervention: Survey
Description: Survey: 38 preselected patient and parent reported outcomes; rating scale: 9 point likert scale (1=not at all important - 9=very important)

Intervention type: OTHER
Intervention: Survey
Description: Survey: 38 preselected patient and parent reported outcomes; rating scale: 9 point likert scale (1=not at all important - 9=very important)
Study: NCT02067741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR1447
Description: 400 mg, corresponding to two 4 g stick packs applications twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR1447
Description: 400 mg, corresponding to two 4 g stick packs applications twice daily
Study: NCT02816372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tidal volume reduction to 4 ml/kg Predicted Body Weight (PBW)
Description: Tidal volume reduction to 4 ml/kg predicted body weight from inclusion to weaning PEEP trial
Study: NCT00979680

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: High-Dose radiotherapy
Description: Preoperative radiotherapy of 45 Gy/25 fractions of 1.8 Gy through three fields was delivered to the pelvis over 5 weeks, followed by a 18 Gy/10 fraction boost to the primary tumor over 2 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemo-radiotherapy
Description: Chemotherapy (5-fluorouracil, 200 mg per square meter of body-surface area per day) was delivered over 5 weeks concurrently with the pelvic radiotherapy.
Study: NCT00712426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creatine Monohydrate
Description: Up to 40 grams daily, powder form creatine monohydrate, taken for the trial duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Up to 40 grams daily, powder form placebo (inactive substance), taken for the trial duration
Study: NCT00435396

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A
Description: Intramuscular injection, 3 doses
Study: NCT02637375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT02232490

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepcortespenlisimut-L
Description: hepcortespenlisimut-L (V5) is given in experimental arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01947634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ResMed Apnea Link plus
Description: Overnight respiratory polygraphy to detect sleep-related breathing disorders is performed in Fabry patients
Study: NCT01193036

Intervention type: BEHAVIORAL
Intervention: Part 1: Interview + Questionnaires
Description: Questionnaires to be completed immediately after interview, which will take approximately 15 minutes.

Intervention type: BEHAVIORAL
Intervention: Part 2: Multiple Questionnaires
Description: Questionnaires to be repeated about every 2 weeks for 1 year.
Study: NCT00944749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: h-ATG (ATGAM )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine (Gengraf )
Study: NCT00921726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: 150 mg oral tablets taken five times over 3 days in Regimens A, B, C, and D